ArticleACS chemical neuroscience2010
Cannabinoid conditioned reward and aversion: behavioral and neural processes.
Article in ACS chemical neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Highway to hell or magic smoke? The dose-dependence of ΔLearning & memory (Cold Spring Harbor, N.Y.) · 2018Pooled it
- Genetic risk for schizophrenia modulates WIN 55,212-2 reward: Evidence from a heterozygous transmembrane domain neuregulin 1 mutant mouse model.Psychopharmacology · 2026Article
- The role of the kynurenine pathway in conditioned place aversion induced by synthetic cannabinoid CP-55940.Behavioral and brain functions : BBF · 2026Article
- ΔCannabis and cannabinoid research · 2024Article
- Place conditioning in humans: opportunities for translational research.Psychopharmacology · 2023Article
- An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products.Molecules (Basel, Switzerland) · 2023Review
- Prolonged efavirenz exposure reduces peripheral oxytocin and vasopressin comparable to known drugs of addiction in male Sprague Dawley rats.IBRO neuroscience reports · 2021Article
- Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.Journal of neurochemistry · 2021Review
- Astroglial CB1 Cannabinoid Receptors Mediate CP 55,940-Induced Conditioned Place Aversion Through Cyclooxygenase-2 Signaling in Mice.Frontiers in cellular neuroscience · 2021Article
- Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.Pharmacology, biochemistry, and behavior · 2020Article
- Cannabinoid disruption of learning mechanisms involved in reward processing.Learning & memory (Cold Spring Harbor, N.Y.) · 2018Review
- Cannabinoid reward and aversion effects in the posterior ventral tegmental area are mediated through dissociable opiate receptor subtypes and separate amygdalar and accumbal dopamine receptor substrates.Psychopharmacology · 2017Article
- Synthetic Pot: Not Your Grandfather's Marijuana.Trends in pharmacological sciences · 2017Review
- Cannabinoid modulation of drug reward and the implications of marijuana legalization.Brain research · 2015Review
- Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.Psychopharmacology · 2015Article
- Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2012Review
- Do initial responses to drugs predict future use or abuse?Neuroscience and biobehavioral reviews · 2012Review
- Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion.Neuroscience letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
The discovery that delta-9-tetrahydrocannabinol (Δ(9)-THC) is the primary psychoactive ingredient in marijuana prompted research that helped elucidate the endogenous cannabinoid system of the brain. Δ(9)-THC and other cannabinoid ligands with agonist action (CP 55,940, HU210, and WIN 55,212-2) increase firing of dopamine neurons and increase synaptic dopamine in brain regions associated with reward and drug addiction. Such changes in cellular processes have prompted investigators to examine the conditioned rewarding effects of the cannabinoid ligands using the place conditioning task with rats and mice. As reviewed here, these cannabinoid ligands can condition place preferences (evidence for rewarding effects) and place aversions (evidence for aversive qualities). Notably, the procedural details used in these place conditioning studies have varied across laboratories. Such variation includes differences in apparatus type, existence of procedural biases, dose, number of conditioning trials, injection-to-placement intervals, and pre-training drug exposure. Some differences in outcome across studies can be explained by these procedural variables. For example, low doses of Δ(9)-THC appear to have conditioned rewarding effects, whereas higher doses have aversive effects that either mask these rewarding effects or condition a place aversion. Throughout this review we highlight key areas that need further research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.